CSIMarket
 


Genocea Biosciences Inc   (GNCA)
Other Ticker:  
 
 

GNCA's Operating Income Growth by Quarter and Year

Genocea Biosciences Inc 's Operating Income results by quarter and year




GNCA Operating Income (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December - -13.41 -11.71 -9.86
III Quarter September - -11.72 -10.74 -9.58
II Quarter June - -14.55 -11.16 -10.07
I Quarter March -15.77 -12.42 -13.38 -9.48
FY   -15.77 -52.10 -46.99 -38.99



GNCA Operating Income first quarter 2022 Y/Y Growth Comment
Genocea Biosciences Inc in the first quarter 2022 recorded Operating Loss of $ -15.77 millions.

According to the results reported in the first quarter 2022, Genocea Biosciences Inc achieved the best Operating Income growth in Biotechnology & Pharmaceuticals industry. While Genocea Biosciences Inc ' s Operating Income no change of % ranks overall at the positon no. in the first quarter 2022.

Explain Operating Income growth


GNCA Operating Income ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Genocea Biosciences Inc 's first quarter 2022 Operating Income $ -15.77 millions GNCA's Income Statement
Genocea Biosciences Inc 's first quarter 2021 Operating Income $ -12.42 millions Quarterly GNCA's Income Statement
New: More GNCA's historic Operating Income Growth >>


GNCA Operating Income (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Operating Income first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Operating Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Operating Income first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Operating Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Operating Income by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Genocea Biosciences Inc 's Q/Q Operating Income Growth


Operating Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


GNCA's I. Quarter Q/Q Operating Income Comment
Current Operating Loss of -15.77 millions by Genocea Biosciences Inc look even more unfavourable compare to the -13.41 millions a quarter before.

Within Biotechnology & Pharmaceuticals industry Genocea Biosciences Inc achieved highest sequential Operating Income growth. While Genocea Biosciences Inc 's Operating Income growth quarter on quarter, overall rank is .


Operating Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Operating Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Operating Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


GNCA's I. Quarter Q/Q Operating Income Comment
Recent results of -15.77 millions by Genocea Biosciences Inc come out even less good considering the Operating Loss -13.41 millions in the fourth quarter.

Within Biotechnology & Pharmaceuticals industry Genocea Biosciences Inc achieved highest sequential Operating Income growth. While Genocea Biosciences Inc 's Operating Income growth quarter on quarter, overall rank is .


Genocea Biosciences Inc 's 12 Months Operating Income Growth Year on Year


Operating Income TTM Growth

12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Sep 30 2021)
12 Months Ending
(Jun 30 2021)
12 Months Ending
(Mar 31 2021)
Cumulative Operating Income 12 Months Ending $ -55.44 $ -52.09 $ -50.40 $ -49.42 $ -46.04
Y / Y Operating Income Growth (TTM) - - - - -
Year on Year Operating Income Growth Overall Ranking # # # # #
Seqeuential Operating Income Change (TTM) - - - - -
Seq. Operating Income Growth (TTM) Overall Ranking # # # # #




Cumulative Operating Income growth Comment
Genocea Biosciences Inc ' has realized cumulative trailing twelve months Operating Loss of $ -55 millions in the Mar 31 2022 period.
The results are detiriorating as the cumulative Operating Loss is inflating from $ -52.09 millions in TTM ending quarter Dec 31 2021 and $ -46.989 millions from the TTM period ending Mar 31 2021.

Genocea Biosciences Inc achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. .

Operating Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Operating Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Operating Income growth Comment
Genocea Biosciences Inc ' has realized cumulative trailing twelve months Operating Loss of $ -55 millions in the Mar 31 2022 period.
The business is worsening as the cumulative Operating Loss is getting bigger from $ -52.09 millions for the period from Dec 31 2021 to Mar 31 2021 and $ -46.989 millions for the twelve months ending in the quarter Mar 31 2021 Sara Claes told.

Genocea Biosciences Inc achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. .

Operating Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Operating Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Operating Income Growth
Biotechnology & Pharmaceuticals Industry Operating Income Growth Trends and Statistics
Healthcare Sector Operating Income Growth Statistics
Operating Income Growth Trends for overall market
GNCA's Operating Income Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Operating Income Growth
Lowest Ranking Operating Income Growth
Operating Income Growth for GNCA's Competitors
Operating Income Growth for Genocea Biosciences Inc 's Suppliers
Operating Income Growth for GNCA's Customers

You may also want to know
GNCA's Annual Growth Rates GNCA's Profitability Ratios GNCA's Asset Turnover Ratio GNCA's Dividend Growth
GNCA's Roe GNCA's Valuation Ratios GNCA's Financial Strength Ratios GNCA's Dividend Payout Ratio
GNCA's Roa GNCA's Inventory Turnover Ratio GNCA's Growth Rates GNCA's Dividend Comparisons



Companies with similar Operating Income no change for the quarter ending Mar 31 2022 within Healthcare SectorY/Y Change %Operating Income for the quarter ending Mar 31 2022
Iqvia Holdings Inc 44.74%$ 44.737 millions
The Pennant Group Inc 44.20%$ 44.203 millions
Abcellera Biologics Inc 42.31%$ 42.307 millions
Bio rad Laboratories Inc 42.20%$ 42.197 millions
Abbott Laboratories38.07%$ 38.075 millions
Corcept Therapeutics Inc36.31%$ 36.312 millions
Medpace Holdings Inc 34.88%$ 34.883 millions
Bio techne Corp31.80%$ 31.797 millions
Bristol myers Squibb Company27.79%$ 27.790 millions
Ironwood Pharmaceuticals inc 27.42%$ 27.420 millions
Boston Scientific Corporation25.95%$ 25.946 millions
Tenet Healthcare Corp24.62%$ 24.615 millions
Glucotrack Inc 21.99%$ 21.987 millions
Syneos Health Inc 21.11%$ 21.111 millions
Charles River Laboratories International inc 20.27%$ 20.270 millions
Ufp Technologies Inc 20.00%$ 20.000 millions
Incyte Corporation17.96%$ 17.959 millions
Amgen Inc 17.43%$ 17.426 millions
Vertex Pharmaceuticals Inc17.24%$ 17.241 millions
Utah Medical Products Inc16.31%$ 16.307 millions
Organon and Co 15.91%$ 15.914 millions
Sotera Health Company15.37%$ 15.374 millions
Avantor Inc 15.28%$ 15.284 millions
Abbvie inc 14.96%$ 14.965 millions
Atrion Corporation14.77%$ 14.769 millions
Edwards Lifesciences Corporation14.42%$ 14.420 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com